A clinical study to assess if a new investigational medicinal product called JJP-1212 is safe, tolerable and able to induce a specific immune response in humans

Status

Recruiting

Phases

Phase 1

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2023-508661-33-00

Acronym

JJP-1212-01-01

Enrollment

Registered

2024-05-27

Start date

2024-05-29

Completion date

Unknown

Last updated

2025-10-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Linear IgA dermatosis (LAD)

None listed

Sex/Gender

All

Age

18 Years to No maximum

Bulgaria, Poland

None listed

Source: EU CTIS · Data processed: Feb 4, 2026